高级检索
当前位置: 首页 > 详情页

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Beijing, Peoples R China
出处:
ISSN:

关键词: Squamous cell carcinoma of head and neck clinical pathology clinical protocols

摘要:
Background: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients. Methods: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I-IV, T1-4a, N0-2, M0). The intervention treatment methods for stage I-II patients are as follows: surgery, induction chemotherapy (IC) + surgery, surgery + adjuvant therapy; The intervention treatment methods for stage III-IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. Results: From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%. Conclusions: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification.

基金:

基金编号: 82072997 82071032

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 医学:研究与实验
最新[2025]版:
JCR分区:
出版当年[2020]版:
Q3 ONCOLOGY Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Beijing, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Beijing, Peoples R China [*1]Capital Med Univ, Beijing Tongren Hosp, 1 Dongjiaomin Lane, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25471 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)